Publications
24
Citations
148
Est. group size
—
Recurring co-author estimate
Active years
6
Publishing since 2021
Alexander W. Rankin's research focuses on CAR T-cell therapies (engineered immune cells) for treating relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and related blood cancers in children, adolescents, and young adults. His work spans clinical trials of CD19 and CD19/CD22 dual-targeting CAR T-cell products, analysis of treatment toxicities and resistance, and strategies to detect and manage relapse after immunotherapy. This research area would suit students interested in pediatric hematology-oncology, cellular immunotherapy, and clinical/translational cancer research.
Publication output was minimal or absent from 2017-2020, then increased notably starting in 2021 with a peak of 7 publications in 2024, suggesting growing recent research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review
Blood Advances · 2026
- Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias
Molecular Therapy Oncology · 2026
- CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results
Journal for ImmunoTherapy of Cancer · 2026
- Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Blood · 2025
- Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival
Journal for ImmunoTherapy of Cancer · 2025
- Quadriparesis after CD19 × CD22 bicistronic chimeric antigen receptor T cells for B‐cell acute lymphoblastic leukaemia
British Journal of Haematology · 2025
- Prospective Study Utilizing PET-CT and Next-Generation Sequencing to Evaluate for Peri-CAR T-Cell Non-CNS Extramedullary Disease in B-Acute Lymphoblastic Leukemia
Transplantation and Cellular Therapy · 2025
- CD19/22 CAR T-cells in children and young adults with B-ALL: Final Phase 1 trial results
Blood · 2025
- Evolving strategies for addressing CAR T-cell toxicities
Cancer and Metastasis Reviews · 2024
- Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy
Expert Review of Clinical Immunology · 2024
- Incidence of preexisting B-cell aplasia in B-ALL: implications for post–CAR T-cell monitoring
Blood Advances · 2024
- CD19 CAR T cells for multiple sclerosis: Forging further into the new frontier
Med · 2024
- Characterization of Extramedullary Disease (EMD) Response to CD19 Targeted Chimeric Antigen Receptor T-Cells (CART) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Multi-Site, Retrospective Cohort Review
Transplantation and Cellular Therapy · 2024
- Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies
Blood · 2024
- Preliminary Safety and Tolerability of CD19x22 CAR-T Cell Therapy in Adolescent and Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Blood · 2024
- Blood×8
- Blood Advances×2
- Journal for ImmunoTherapy of Cancer×2
- Transplantation and Cellular Therapy×2
- British Journal of Haematology×2
- Daniel Li
Medicine · The Ohio State University
- Audrey M. Sigmund
Medicine · The Ohio State University
- Utkarsh Acharya
Medicine · The Ohio State University
- Lingling Liu
Medicine · The Ohio State University
- Jiasheng Wang
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile